Description

• Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia, approved for sale by the U.S
• Food and Drug Administration (FDA) in 2014
• The U.S
• Drug Enforcement Administration (DEA) has scheduled this substance as controlled substance, as it may lead to physical or psychological dependence
• This stable-labeled internal standard is suitable for use in quantitation of suvorexant levels by GC/MS or LC/MS for applications in clinical toxicology, therapeutic drug monitoring or urine drug testing.